Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players.

Autor:	Miner AE; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA., Groh JR; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA., Tripodis Y; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA., Adler CH; Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA., Balcer LJ; Departments of Neurology, Population Health and Ophthalmology, NYU Grossman School of Medicine, New York, New York, USA., Bernick C; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA., Zetterberg H; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA., Blennow K; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Pitié-Salpêtrière Hospital 47, Paris, France.; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, University of Science, Hefei, China., Peskind E; Veterans Affairs Northwest Mental Illness Research, Education, and Clinical Center, Seattle, Washington, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA., Ashton NJ; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden., Gaudet CE; Physical Medicine & Rehabilitation Service, VA Boston Healthcare System, Boston, Massachusetts, USA., Martin B; Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, Massachusetts, USA., Palmisano JN; Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, Massachusetts, USA., Banks SJ; Departments of Neuroscience and Psychiatry, University of California, San Diego, California, USA., Barr WB; Department of Neurology, NYU Grossman School of Medicine, New York City, New York, USA., Wethe JV; Department of Psychiatry and Psychology, Mayo Clinic School of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA., Cantu RC; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Boston University Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA., Dodick DW; Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA., Katz DI; Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Encompass Health Braintree Rehabilitation Hospital, Braintree, Massachusetts, USA., Mez J; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Boston University Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA., van Amerongen S; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands., Cummings JL; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, Nevada, USA., Shenton ME; Psychiatry Neuroimaging Laboratory, Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Reiman EM; Banner Alzheimer's Institute, University of Arizona, Arizona State University, Translational Genomics Research Institute, and Arizona Alzheimer's Consortium, Phoenix, Arizona, USA., Stern RA; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Boston University Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Neurosurgery, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Anatomy & Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA., Alosco ML; Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Boston University Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; Department of Anatomy & Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov; Vol. 20 (11), pp. 7529-7546. Date of Electronic Publication: 2024 Oct 01.
DOI:	10.1002/alz.14231
Abstrakt:	Introduction: Blood-based biomarkers offer a promising approach for the detection of neuropathologies from repetitive head impacts (RHI). We evaluated plasma biomarkers of amyloid, tau, neurodegeneration, and inflammation in former football players. Methods: The sample included 180 former football players and 60 asymptomatic, unexposed male participants (aged 45-74). Plasma assays were conducted for beta-amyloid (Aβ) 40, Aβ42, hyper-phosphorylated tau (p-tau) 181+231, total tau (t-tau), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), Aβ42/p-tau181 and Aβ42/Aβ40 ratios. We evaluated their ability to differentiate the groups and associations with RHI proxies and traumatic encephalopathy syndrome (TES). Results: P-tau181 and p-tau231(p adj  = 0.016) were higher and Aβ42/p-tau181 was lower(p adj  = 0.004) in football players compared to controls. Discrimination accuracy for p-tau was modest (area under the curve [AUC] = 0.742). Effects were not attributable to AD-related pathology. Younger age of first exposure (AFE) correlated with higher NfL (p adj  = 0.03) and GFAP (p adj  = 0.033). Plasma GFAP was higher in TES-chronic traumatic encephalopathy (TES-CTE) Possible/Probable (p adj  = 0.008). Discussion: Plasma p-tau181 and p-tau231, GFAP, and NfL may offer some usefulness for the characterization of RHI-related neuropathologies. Highlights: Former football players had higher plasma p-tau181 and p-tau231 and lower Aβ42/ptau-181 compared to asymptomatic, unexposed men. Younger age of first exposure was associated with increased plasma NfL and GFAP in older but not younger participants. Plasma GFAP was higher in participants with TES-CTE possible/probable compared to TES-CTE no/suggestive. (© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text